Education
About Us
Working with TipRanks
Follow Us
Drugs Made In America Acquisition Corp. (DMAA)
NASDAQ:DMAA
Total Valuation
Drugs Made In America Acquisition Corp. has a market cap or net worth of $347.24M. The enterprise value is ―.
Market Cap$347.24M
Enterprise Value―
Share Statistics
Drugs Made In America Acquisition Corp. has 33,517,143 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,517,143
Owned by Insiders―
Owned by Institutions51.14%
Financial Efficiency
Drugs Made In America Acquisition Corp.’s return on equity (ROE) is 1.96 and return on invested capital (ROIC) is -8.86%.
Return on Equity (ROE)1.96
Return on Assets (ROA)-0.87
Return on Invested Capital (ROIC)-8.86%
Return on Capital Employed (ROCE)1.96
Revenue Per Employee0.00
Profits Per Employee-239.50
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Drugs Made In America Acquisition Corp. is 61.5. Drugs Made In America Acquisition Corp.’s PEG ratio is 0.00.
PE Ratio61.5
PS Ratio0.00
PB Ratio-349.87K
Price to Fair Value-349.87K
Price to FCF-289.38K
Price to Operating Cash Flow-573.71
PEG Ratio0.00
Income Statement
In the last 12 months, Drugs Made In America Acquisition Corp. had revenue of 0.00 and earned -479.00 in profits. Earnings per share was -0.06.
Revenue0.00
Gross Profit0.00
Operating Income-479.00
Pretax Income-479.00
Net Income-479.00
EBITDA0.00
Earnings Per Share (EPS)-0.06
Cash Flow
In the last 12 months, operating cash flow was -414.13K and capital expenditures 0.00, giving a free cash flow of -414.13K billion.
Operating Cash Flow-414.13K
Free Cash Flow-414.13K
Free Cash Flow per Share-0.01
Dividends & Yields
Drugs Made In America Acquisition Corp. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta<0.01
52-Week Price Change3.91%
50-Day Moving Average10.31
200-Day Moving Average―
Relative Strength Index (RSI)63.56
Average Volume (3m)49.15K
Important Dates
Drugs Made In America Acquisition Corp. upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Drugs Made In America Acquisition Corp. as a current ratio of 6.27, with Debt / Equity ratio of 0.00%
Current Ratio6.27
Quick Ratio6.27
Debt to Market Cap<0.01
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Drugs Made In America Acquisition Corp. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Drugs Made In America Acquisition Corp. EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -289.38K.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-289.38K
EV to Operating Cash Flow-289.38K
Balance Sheet
Drugs Made In America Acquisition Corp. has $717.00 in cash and marketable securities with $0.00 in debt, giving a net cash position of $717.00 billion.
Cash & Marketable Securities$717.00
Total Debt$0.00
Net Cash$717.00
Net Cash Per Share<$0.01
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Drugs Made In America Acquisition Corp. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―